PT2198007T - Composições farmacêuticas contendo toxoides a e b de clostridium difficile - Google Patents

Composições farmacêuticas contendo toxoides a e b de clostridium difficile

Info

Publication number: PT2198007T
Authority: PT; Portugal
Prior art keywords: pharmaceutical compositions; compositions containing; clostridium difficile; containing clostridium; difficile toxoids
Prior art date: 2007-09-14

Application number

PT88302104T

Other languages

English (en)

Inventor

Russell Middaugh C

Fahrner Richard

Ciarametaro Peter

Original Assignee

Sanofi Pasteur Biologics Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-14

Filing date

2008-09-15

Publication date

2018-01-29

2008-09-15 Application filed by Sanofi Pasteur Biologics Llc filed Critical Sanofi Pasteur Biologics Llc

2018-01-29 Publication of PT2198007T publication Critical patent/PT2198007T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Mycology (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Zoology (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT88302104T 2007-09-14 2008-09-15 Composições farmacêuticas contendo toxoides a e b de clostridium difficile PT2198007T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US97249607P	2007-09-14	2007-09-14

Publications (1)

Publication Number	Publication Date
PT2198007T true PT2198007T (pt)	2018-01-29

Family

ID=40452372

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT88302104T PT2198007T (pt)	2007-09-14	2008-09-15	Composições farmacêuticas contendo toxoides a e b de clostridium difficile

Country Status (21)

Country	Link
US (3)	US9320790B2 (pt)
EP (3)	EP4537849A3 (pt)
JP (3)	JP5503543B2 (pt)
KR (2)	KR20160005378A (pt)
CN (2)	CN101855336B (pt)
AU (1)	AU2008299885C1 (pt)
BR (1)	BRPI0816790A8 (pt)
CA (1)	CA2699435A1 (pt)
CY (1)	CY1119979T1 (pt)
DK (1)	DK2198007T3 (pt)
ES (2)	ES3001561T3 (pt)
HR (1)	HRP20180054T1 (pt)
HU (1)	HUE037932T2 (pt)
IL (1)	IL204366A (pt)
MX (1)	MX2010002815A (pt)
NO (1)	NO2198007T3 (pt)
PL (1)	PL2198007T3 (pt)
PT (1)	PT2198007T (pt)
RU (1)	RU2550271C2 (pt)
SI (1)	SI2198007T1 (pt)
WO (1)	WO2009035707A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101855336B (zh)	2007-09-14	2019-07-30	赛诺菲巴斯德生物制剂有限责任公司	含艰难梭菌类毒素a和b的药物组合物
JP6121421B2 (ja)	2010-09-03	2017-04-26	バルネバオーストリアジーエムビーエイチ	Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
GB201105981D0 (en) *	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
AU2012245904B2 (en) *	2011-04-22	2016-04-21	Wyeth Llc	Compositions relating to a mutant Clostridium difficile toxin and methods thereof
KR101135486B1 (ko) *	2011-05-25	2012-04-13	함종욱	보툴리눔 에이형 독소의 액상제품
BR122016023101B1 (pt)	2012-10-21	2022-03-22	Pfizer Inc	Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
RU2670943C9 (ru)	2012-11-08	2018-11-26	Илэвэн Байотерапьютикс, Инк.	Антагонисты ил-6 и их применение
LT2928489T (lt)	2012-12-05	2019-04-10	Glaxosmithkline Biologicals S.A.	Imunogeninė kompozicija
SG10201801459SA (en)	2013-03-14	2018-03-28	Takeda Vaccines Inc	Compositions and methods for live, attenuated alphavirus formulations
BR112015023469A8 (pt) *	2013-03-15	2019-12-03	Sanofi Pasteur Inc	toxóides, composições e métodos relacionados
JP2016516721A (ja) *	2013-03-15	2016-06-09	サノフィパストゥールインコーポレイテッド	トキソイド、組成物および関連方法
SG11201510166YA (en)	2013-06-14	2016-01-28	Sanofi Pasteur Inc	Compositions and methods of immunizing against c. difficile
PL3010537T3 (pl)	2013-06-17	2019-03-29	De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport	Sposoby zapobiegania agregacji komponentów wirusowych
US9930893B2 (en) *	2014-02-10	2018-04-03	The Johns Hopkins University	Inhibitors of DXP synthase and methods of use thereof
MY185114A (en)	2014-11-07	2021-04-30	Sesen Bio Inc	Improved il-6 antibodies
BR112017024443A2 (pt)	2015-05-15	2018-10-23	Sanofi Pasteur Inc	métodos para imunização contra clostridium difficile
BE1023343B1 (nl) *	2015-05-20	2017-02-09	Mycartis Nv	Opslagbuffer
CN108718522A (zh) *	2016-02-23	2018-10-30	赛森生物股份有限公司	Il-6拮抗剂制剂及其用途
CN117959415A (zh)	2016-09-13	2024-05-03	阿勒根公司	非蛋白质梭菌毒素组合物
CN112512480B (zh) *	2018-05-21	2024-10-01	中外制药株式会社	被封入玻璃容器的冷冻干燥制剂
WO2021255690A2 (en) *	2020-06-19	2021-12-23	Pfizer Inc.	Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4879218A (en) *	1982-09-13	1989-11-07	Virginia Tech Intellectual Properties, Inc.	Antibody for C.difficile
US5736139A (en) *	1989-10-31	1998-04-07	Ochidian Pharmaceuticals, Inc.	Treatment of Clostridium difficile induced disease
JPH03193735A (ja)	1989-12-22	1991-08-23	Shionogi & Co Ltd	グリコペプチド系抗生物質の安定化組成物
ZA927923B (en) *	1991-10-16	1993-04-26	Schering Corp	Lipophilic oligosaccharide antibiotic salt compositions.
CA2138020C (en)	1992-06-23	1999-02-16	Eric A. Johnson	Pharmaceutical composition containing botulinum b complex
US5562909A (en)	1993-07-12	1996-10-08	Massachusetts Institute Of Technology	Phosphazene polyelectrolytes as immunoadjuvants
US5902565A (en) *	1993-12-24	1999-05-11	Csl Limited	Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US5512547A (en) *	1994-10-13	1996-04-30	Wisconsin Alumni Research Foundation	Pharmaceutical composition of botulinum neurotoxin and method of preparation
JPH08333277A (ja)	1995-06-05	1996-12-17	Hoechst Japan Ltd	ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
JPH11510793A (ja) *	1995-07-07	1999-09-21	オラバックスインク．	胃腸病に対する鼻腔内ワクチン接種
US5932223A (en)	1996-09-26	1999-08-03	Merck & Co., Inc.	Rotavirus vaccine formulations
ATE346931T1 (de) *	1997-06-20	2006-12-15	Intervet Int Bv	Clostridium perfringens impfstoff
US6969520B2 (en) *	1997-10-20	2005-11-29	Acambis Inc.	Active immunization against clostridium difficile disease
EP1568378B1 (en)	1997-10-20	2016-03-16	Sanofi Pasteur Biologics, LLC	Immunization against Clostridium difficile disease
US6214341B1 (en) *	1997-10-20	2001-04-10	Oravax	Passive immunization against Clostridium difficile disease
US6013635A (en) *	1998-05-28	2000-01-11	Synsorb Biotech, Inc.	Treatment of C. difficile toxin B associated conditions
JP2000117967A (ja) *	1998-10-16	2000-04-25	Fuji Photo Film Co Ltd	インクジェット記録方法
FR2791895B1 (fr)	1999-03-23	2001-06-15	Pasteur Merieux Serums Vacc	Utilisation de trehalose pour stabiliser un vaccin liquide
TR200103018T2 (tr) *	1999-04-19	2002-02-21	Beecham Biologicals S.A. Smithkline	İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
US6599715B1 (en) *	1999-05-12	2003-07-29	The Regents Of The University Of California	Real time viability detection of bacterial spores
US7780967B2 (en) *	2000-02-08	2010-08-24	Allergan, Inc.	Reduced toxicity Clostridial toxin pharmaceutical compositions
DE60334678D1 (de)	2002-02-14	2010-12-09	Chugai Pharmaceutical Co Ltd	Antikörper enthaltende pharmazeutische lösungen
AU2003225057A1 (en) *	2002-04-19	2003-11-03	The Regents Of The University Of Michigan	Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens
US20040235139A1 (en) *	2002-12-23	2004-11-25	Demain Arnold L.	Clostridium difficile culture and toxin production methods
DE10333317A1 (de) *	2003-07-22	2005-02-17	Biotecon Therapeutics Gmbh	Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
JP4671864B2 (ja)	2003-10-09	2011-04-20	中外製薬株式会社	タンパク質溶液の安定化方法
KR100852824B1 (ko) *	2004-07-26	2008-08-18	메르츠 파마 게엠베하 운트 코. 카가아	보툴리눔 신경독소를 포함하는 치료 조성물
EP1802349A1 (en)	2004-10-13	2007-07-04	Ilypsa, Inc.	Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
FR2881139A1 (fr)	2005-01-26	2006-07-28	Agronomique Inst Nat Rech	Composition pour la lyophilisation de proteines
BRPI0613001B8 (pt)	2005-10-06	2021-05-25	Allergan Inc	composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína
US8137677B2 (en)	2005-10-06	2012-03-20	Allergan, Inc.	Non-protein stabilized clostridial toxin pharmaceutical compositions
WO2007044809A2 (en) *	2005-10-11	2007-04-19	Botulinum Toxin Research Associates, Inc.	Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
US9132184B2 (en)	2006-11-07	2015-09-15	Sanofi Pasteur Biologics, Llc	Stabilization of vaccines by lyophilization
CN101855336B (zh)	2007-09-14	2019-07-30	赛诺菲巴斯德生物制剂有限责任公司	含艰难梭菌类毒素a和b的药物组合物
SG171934A1 (en)	2008-12-03	2011-07-28	Boehringer Ingelheim Vetmed	Process for production of vaccines

2008
- 2008-09-15 CN CN200880116603.0A patent/CN101855336B/zh active Active
- 2008-09-15 US US12/677,864 patent/US9320790B2/en active Active
- 2008-09-15 CN CN201610227574.1A patent/CN106039299A/zh active Pending
- 2008-09-15 KR KR1020157036693A patent/KR20160005378A/ko not_active Abandoned
- 2008-09-15 BR BRPI0816790A patent/BRPI0816790A8/pt not_active IP Right Cessation
- 2008-09-15 RU RU2010114730/10A patent/RU2550271C2/ru not_active IP Right Cessation
- 2008-09-15 ES ES16174817T patent/ES3001561T3/es active Active
- 2008-09-15 EP EP24220340.4A patent/EP4537849A3/en active Pending
- 2008-09-15 PT PT88302104T patent/PT2198007T/pt unknown
- 2008-09-15 EP EP08830210.4A patent/EP2198007B1/en not_active Not-in-force
- 2008-09-15 PL PL08830210T patent/PL2198007T3/pl unknown
- 2008-09-15 CA CA2699435A patent/CA2699435A1/en not_active Abandoned
- 2008-09-15 NO NO08830210A patent/NO2198007T3/no unknown
- 2008-09-15 JP JP2010524889A patent/JP5503543B2/ja active Active
- 2008-09-15 DK DK08830210.4T patent/DK2198007T3/en active
- 2008-09-15 AU AU2008299885A patent/AU2008299885C1/en not_active Ceased
- 2008-09-15 SI SI200831906T patent/SI2198007T1/en unknown
- 2008-09-15 EP EP16174817.3A patent/EP3124044B8/en active Active
- 2008-09-15 HU HUE08830210A patent/HUE037932T2/hu unknown
- 2008-09-15 WO PCT/US2008/010767 patent/WO2009035707A1/en not_active Ceased
- 2008-09-15 KR KR1020107007994A patent/KR101679812B1/ko not_active Expired - Fee Related
- 2008-09-15 HR HRP20180054TT patent/HRP20180054T1/hr unknown
- 2008-09-15 ES ES08830210.4T patent/ES2657485T3/es active Active
- 2008-09-15 MX MX2010002815A patent/MX2010002815A/es unknown
2010
- 2010-03-09 IL IL204366A patent/IL204366A/en active IP Right Grant
2013
- 2013-11-22 JP JP2013241821A patent/JP6258674B2/ja active Active
2016
- 2016-03-29 US US15/083,428 patent/US9687541B2/en active Active
- 2016-10-31 JP JP2016212540A patent/JP2017052773A/ja active Pending
2017
- 2017-06-26 US US15/632,480 patent/US10639362B2/en active Active
2018
- 2018-01-23 CY CY20181100084T patent/CY1119979T1/el unknown

Also Published As

Publication number	Publication date
AU2008299885C1 (en)	2015-06-25
KR20160005378A (ko)	2016-01-14
EP2198007B1 (en)	2017-10-25
HUE037932T2 (hu)	2018-09-28
US10639362B2 (en)	2020-05-05
BRPI0816790A2 (pt)	2014-10-14
MX2010002815A (es)	2010-07-30
US20180000920A1 (en)	2018-01-04
PL2198007T3 (pl)	2018-03-30
US20110045025A1 (en)	2011-02-24
DK2198007T3 (en)	2018-01-15
WO2009035707A1 (en)	2009-03-19
EP2198007A4 (en)	2012-03-07
RU2010114730A (ru)	2011-10-20
ES2657485T3 (es)	2018-03-05
KR20100075912A (ko)	2010-07-05
HRP20180054T1 (hr)	2018-02-09
US9687541B2 (en)	2017-06-27
BRPI0816790A8 (pt)	2017-05-16
RU2550271C2 (ru)	2015-05-10
WO2009035707A9 (en)	2010-06-10
EP3124044C0 (en)	2024-12-18
AU2008299885B2 (en)	2014-12-11
IL204366A (en)	2013-02-28
US20160317640A1 (en)	2016-11-03
CA2699435A1 (en)	2009-03-19
JP2014055174A (ja)	2014-03-27
CN106039299A (zh)	2016-10-26
JP6258674B2 (ja)	2018-01-10
EP3124044B8 (en)	2025-01-22
SI2198007T1 (en)	2018-04-30
EP2198007A1 (en)	2010-06-23
JP2017052773A (ja)	2017-03-16
EP3124044A1 (en)	2017-02-01
JP2010539172A (ja)	2010-12-16
EP4537849A2 (en)	2025-04-16
CN101855336A (zh)	2010-10-06
AU2008299885A1 (en)	2009-03-19
EP4537849A3 (en)	2025-07-09
US9320790B2 (en)	2016-04-26
KR101679812B1 (ko)	2016-11-28
CY1119979T1 (el)	2018-12-12
CN101855336B (zh)	2019-07-30
JP5503543B2 (ja)	2014-05-28
NO2198007T3 (pt)	2018-03-24
ES3001561T3 (en)	2025-03-05
EP3124044B1 (en)	2024-12-18

Publication	Publication Date	Title
HUE037932T2 (hu)	2018-09-28	Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
IL220509A (en)	2016-07-31	Compressed pyridinylpyrolidone, a pharmaceutical preparation and combination
IL247741A0 (en)	2016-11-30	pharmaceutical preparations
IL216256A0 (en)	2012-01-31	A pharmaceutical composition
EP2001497A4 (en)	2012-11-07	PHARMACEUTICAL COMPOSITIONS
PL2285357T3 (pl)	2014-08-29	Kompozycja farmaceutyczna zawierająca brivaracetam
HUE044237T2 (hu)	2019-10-28	Kortexolon-17-alfa-propionátot tartalmazó gyógyszerészeti kompozíciók
EP2222313A4 (en)	2011-02-16	PHARMACEUTICAL COMPOSITIONS
PL2285413T3 (pl)	2013-01-31	Kompozycja farmaceutyczna
IL202306A (en)	2014-07-31	Pharmaceutical preparations containing stabilized thrombin
IL200313A0 (en)	2010-04-29	A lactase formulation
IL247086A0 (en)	2016-09-29	Nitrogen-containing compounds and pharmaceutical preparations
IL195039A0 (en)	2009-08-03	Pharmaceutical compositions containing oridonin
GB0712389D0 (en)	2007-08-01	A Pharmaceutical composition
EP2146695A4 (en)	2010-05-19	PHARMACEUTICAL COMPOSITIONS
ZA201008115B (en)	2012-01-25	A solid pharmaceutical formulation
GB0709811D0 (en)	2007-07-04	Pharmaceutical compositions
GB2480585B (en)	2014-05-21	A tablet composition
GB0712454D0 (en)	2007-08-08	Pharmaceutical compositions
ZA201105447B (en)	2012-12-27	Compositions and dosage regimes comprising a clostridial vaccine and levamisole
HU0700755D0 (en)	2008-01-28	Pharmaceutical compositions containing capsaicionid
IL201394A0 (en)	2010-05-31	Niacin - based pharmaceutical compositions
GB0723018D0 (en)	2008-01-02	Pharmaceutical compositions
IL181181A0 (en)	2008-01-20	A pharmaceutical composition extracted from plants
GB0709603D0 (en)	2007-06-27	Pharmaceutical compositions